Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.  They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that TPX-0022, the company's inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R, has been granted orphan drug designation by the Food and Drug Administration (FDA) for the treatment of patients with gastric cancer, including gastroesophageal junction adenocarcinoma.

Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question-and-answer session at the 42nd annual Goldman Sachs Healthcare Conference on June 9.

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors. Garry Nicholson, who is currently the interim chair, will remain on the board.

Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1. Dr. Srinivasan has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business development for the BioPharmaceutical business unit of AstraZeneca.

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer

Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q1 2021 Results - Earnings Call Transcript

Investigational New Drug Application Cleared

Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor

Presentations Planned at Annual Meeting of American Association for Cancer Research, Held Virtually April 9-14 Presentations Planned at Annual Meeting of American Association for Cancer Research, Held Virtually April 9-14

Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates

Turning Point Therapeutics Inc (NASDAQ: TPTX) has reported initial data from the ongoing Phase 1/2 SWORD-1 study evaluating its RET inhibitor drug candidate, TPX-0046, in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. Data from the Phase 1 dose-finding portion of the study showed preliminary clinical activity, including objective responses and a generally well-tolerated safety profile.

Turning Point's RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor Settings

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase 1/2 SWORD-1 study of its RET inhibitor drug candidate, TPX-0046.

Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046

Barbara Bodem Joins Board, Appointed Chair of Audit Committee

Turning Point Therapeutics Announces Board Changes

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced today that four abstracts featuring three of its drug candidates will be presented at the American Association for Cancer Research (AACR) annual meeting, which will convene virtually from April 10-14.

Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting

Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the fourth quarter and year ended Dec. 31, 2020.

Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates

This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?

Why Turning Point Is Turning Heads

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and year ended Dec. 31, 2020 financial results following the close of U.S. financial markets on March 1. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. President and CEO Athena Countouriotis, M.D., will host the call, which will include a question and answer session.

Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call

Oncternal Therapeutics Inc

Organogenesis Holdings

Schnitzer Steel Industries Inc

USANA Health Sciences

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Ascendis Pharma

Guardant Health Inc

If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances that your investments will be successful should increase.

3 Companies With High Quality Balance Sheets to Consider

Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab Company to Participate in Two Q&A Sessions, Including a Joint Discussion with Zai Lab

Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced updated interim findings from the ongoing TRIDENT-1 registrational study of lead drug candidate repotrectinib in patients with ROS1-positive TKI-naïve non-small cell lung cancer (NSCLC).

Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced 2021 milestone targets for its pipeline of four drug candidates, including data updates from multiple clinical studies and the initiation of new clinical studies. The company also updated its cash position as of Dec. 31, 2020.

Turning Point Therapeutics Announces 2021 Milestone Targets

Zai Lab Ltd.

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point's MET/SRC/CSF1R Inhibitor, in Greater China

Turning Point and Zai Lab Broaden Collaboration

TPTX has demonstrated solid competitive data for its lead asset. The company, after two rounds of dilution, is heavy with cash.

Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers

Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Planned for Presentation at Upcoming World Conference on Lung Cancer Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Planned for Presentation at Upcoming World Conference on Lung Cancer

Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor

Insmed

Aurinia Pharmaceuticals

Cytokinetics

NeoGenomics

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Top 10 Healthcare Stocks for the Future

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will present a company overview at the Jefferies Virtual London Healthcare Conference on Nov. 18.

News for Turning Point Therapeutics Stock (TPTX)